<DOC>
	<DOCNO>NCT01121770</DOCNO>
	<brief_summary>The purpose study determine preventative dose study drug , Arixtra速 patient kidney disease . We measure blood level Arixtra速 patient kidney disease develop guideline dose .</brief_summary>
	<brief_title>`` Pharmacokinetic Study Fondaparinux Inpatients With Renal Dysfunction ''</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Inpatients 18 year older estimate creatinine clearance 2050 ml/min current hospitalization cancerrelated abdominal , breast surgery elective orthopedic surgery able give inform consent need prophylactic anticoagulant therapy increase risk thrombotic episode Use follow clopidogrel , aspirin , NSAID usage , ( usage prohibit patient participate study ) body weight &lt; 50 kg anticoagulation therapy thrombosis indication pregnant breastfeeding hypersensitivity Arixtra速 thrombocytopenia associate positive vitro test antiplatelet antibody presence Arixtra速 bacterial endocarditis brain malignancy increase risk bleeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>